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Introduction {#sec001}
============

Bovine leukemia virus (BLV) is an oncogenic virus that causes enzootic bovine leukemia in cattle. This virus is globally distributed, except for Europe, Australia, and New Zealand \[[@pone.0234939.ref001]\]. Most of the infected animals remain asymptomatic, while only 5--10% will develop lymphosarcomas, the final stage of the disease. The main target cell is the B lymphocyte IgM^+^ CD5^+^; nevertheless, it can also infect other cell types \[[@pone.0234939.ref002]\]. Due to its effects on immune cells, it has been associated with an increased incidence of secondary infections. As has been previously reported in the literature, BLV infection could cause a higher incidence of mastitis \[[@pone.0234939.ref003],[@pone.0234939.ref004]\].

The mammary epithelium plays a critical role in the early defense against pathogens that causes mastitis. Besides being a physical barrier to pathogens, bovine mammary epithelial cells (bMEC) express pattern recognition receptors (PRRs), whose activation stimulates cytokine production and immune cell recruitment. Any disturbance in this biological system could impair the normal response of this epithelium to pathogen invasion. Recently, a bovine mammary epithelial cell line was stably infected with BLV *in vitro* (MAC-T BLV) \[[@pone.0234939.ref005]\], showing that these cells are susceptible to productive BLV infection. Moreover, these cells showed reduced viability and TLR2 mRNA expression when exposed to heat-inactivated *S*. *aureus*, suggesting that the innate immune response could be impaired in BLV infected bMEC \[[@pone.0234939.ref006]\]. These findings signal the need for additional studies to better understand the effect of BLV infection on the bovine mammary epithelial immune response. The development of new transcriptome technologies allows us to analyze the global impact of BLV infection on bMEC. The objective was to analyze the transcription profile of BLV infected and uninfected bovine mammary epithelial cells (MAC-T) by next-generation sequencing (NGS). Our results show that BLV infection of the bovine mammary epithelial cell line MAC-T causes increased expression of genes related to the immune response, in addition to altered expression of genes associated with collagen catabolic process, protooncogenes and tumor suppressor genes. The information collected here could help researchers to better understand the viral effect on bMEC.

Materials and methods {#sec002}
=====================

Cell lines and culture conditions {#sec003}
---------------------------------

MAC-T \[[@pone.0234939.ref007]\] (gift from Dr. Juan Loor from University of Illinois) and MAC-T stably infected with BLV (MAC-T BLV) cells were cultured in Modified Eagle\'s medium (MEM) supplemented with 10% fetal bovine serum (MIDSCI, Valley Park, MO, USA) and 1 μg/ml hydrocortisone (Sigma-Aldrich, Saint Louis, MO, USA) at 37°C with 5% CO~2~. MAC-T BLV cells were infected with PBMCs from BLV positive animals from Kansas, United States, as previously described \[[@pone.0234939.ref005]\]. Cultures were passaged upon approaching confluence using standard techniques, and MAC-T cells were always passed in the first place. MAC-T BLV cells were subcultured after MAC-T to avoid cross-contamination. For RNA seq analysis, MAC-T samples were obtained in passages 8, 30, and 36, while the three samples from MAC-T BLV were obtained in passage 35 post-infection (from 3 different infections with BLV). Each biological replicate consisted of MAC-T cells infected with the same batch of PBMCs obtained from a cow infected with BLV. All the cell lines were harvested for RNA extraction when they reached confluency.

RNA extraction and sequencing {#sec004}
-----------------------------

MAC-T and MAC-T BLV cells were grown in a six-well plate until a 100% confluency. After three washes with PBS, the cells were harvested with 600 μL of Trizol® (Thermo Fisher Scientific, Waltham, MA, USA). Total RNA was extracted from 3 samples of MAC-T and 3 samples of MAC-T BLV using the Direct-zol™ RNA MiniPrep Plus kit (Zymo Research, USA). The RNA quality was analyzed by Bioanalyzer (Agilent, USA), following the manufacturer´s instructions. Samples were sequenced by Novogene Corporation ([https://en.novogene.com](https://en.novogene.com/)), who constructed the cDNA library using RNA-NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA, USA). The sequencing performed in the NovaSeq 6000 (Illumina, San Diego, CA, USA) resulted in 150 pb paired-end sequences.

The data sent by Novogene Corporation were analyzed by our laboratory. FastQC analysis in Galaxy \[[@pone.0234939.ref008]\] showed that all the sequences had a score higher than 30, and it was not necessary to filter or trim them. The sequences were aligned against the bovine reference genome bosTau8 using the program HISAT2 \[[@pone.0234939.ref009]\]. The aligned counts were analyzed using GenomicAlignments and GenomicFeatures in R \[[@pone.0234939.ref010]\]. Differentially expressed genes were identified with DESeq2 in R \[[@pone.0234939.ref011]\]. The functional enrichment of differentially expressed genes was performed in Database for Annotation, Visualization, and Integrated Discovery (DAVID, versión 6.7; [http://david.abcc.ncifcrf.gov](http://david.abcc.ncifcrf.gov/)). The principal component analysis, heat map, and volcano plot were done in the platform iDEP. Later, PCA was done in R using the gplots to allow label identification of the samples \[[@pone.0234939.ref012]\].

Results {#sec005}
=======

Comparative transcriptome analysis was performed in uninfected and BLV-infected bovine mammary epithelial cells (MAC-T). A total of 175.041.879 reads were obtained, with an average of 29.173.647 reads in each sample. Approximately 80% of MAC-T reads, and 83% of MAC-T BLV aligned uniquely with the reference genome ([Table 1](#pone.0234939.t001){ref-type="table"}).

10.1371/journal.pone.0234939.t001

###### Summary of the sequences and alignments with the bovine reference genome BosTau8.

![](pone.0234939.t001){#pone.0234939.t001g}

  Sample            Total reads   Unique alignment   Unique alignment (%)   Multiple alignments   Multiple alignments (%)   No alignment   No alignment (%)
  ----------------- ------------- ------------------ ---------------------- --------------------- ------------------------- -------------- ------------------
  **MAC-T 1**       26023368      20893092           80.29                  1853329               7.12                      3276947        12.59
  **MAC-T 2**       25330865      20373892           80.43                  1510347               5.96                      3446626        13.61
  **MAC-T 3**       37707749      30657132           81.30                  2014877               5.34                      5035740        13.35
  **MAC-T BLV 1**   29518689      22753241           77.08                  1935843               6.56                      4829605        16.36
  **MAC-T BLV 2**   27188819      23570428           86.69                  862148                3.17                      2756243        10.14
  **MAC-T BLV 3**   29272389      25223952           86.17                  919302                3.14                      3129135        10.69

From a total of 14193 genes, only 9852 overcome the low expression filter (more than 0.5 CPM in at least one sample). The hierarchical clustering analysis done by the platform IDEP revealed that MAC-T samples segregate differently than MAC-T BLV, suggesting that BLV infection affects the bovine mammary epithelial cell´s transcriptome ([Fig 1](#pone.0234939.g001){ref-type="fig"}). Interestingly, one of the MAC-T BLV biological replicates differ from the other two samples, and this is probably a consequence of biological variations. Some differences are also present among MAC-T samples, probably because they came from a different number of culture passages.

![Heatmap and hierarchical clustering based on the most differentially expressed genes.\
The 1000 most differentially expressed genes between MAC-T (n = 3) and MAC-T BLV (n = 3) are shown.](pone.0234939.g001){#pone.0234939.g001}

Principal component analysis (PCA) is a linear transformation of the data showing the highest variability between the samples ([Fig 2](#pone.0234939.g002){ref-type="fig"}). The first component (PC1) that separates MAC-T from MAC-T BLV represents 40% of the genetic variation between samples and is related to ribosomal complex development and ribosomal RNA metabolism and process. As observed in the heat map, mact 1 sample is quite different from mact2 and mact 3; however, there is no difference in RNA quality between the samples (available in [S1 Text](#pone.0234939.s001){ref-type="supplementary-material"}).

![PCA from MAC-T and MAC-T BLV samples.\
Scatter plots of the first two principal components of the normalized gene expression profiles of MAC-T and MAC-T BLV. The PCA plot shows the variance of the three biological replicates of MAC-T and MAC-T BLV. Each axis represents the percentages of variation explained by the principal components.](pone.0234939.g002){#pone.0234939.g002}

DESeq2 was used to analyze differential gene expression. Genes were filtered by a minimum log2-fold change ≥ 2 (log2FC), 0.05 adjusted p-value, and false discovery rate (FDR) lower than 0.05. With those parameters, 352 differentially expressed genes were found: 211 upregulated and 141 downregulated. [Fig 3](#pone.0234939.g003){ref-type="fig"} displays a volcano plot representing the distribution of the differentially expressed genes. The list of the most differentially expressed genes is shown in [S1 Table](#pone.0234939.s002){ref-type="supplementary-material"}. The five most upregulated genes in MAC-T BLV were OAS1Z, VRTN, B4GALT5, SGCE y CTSL, while the most downregulated were ADAMTS2, TYRP1, GJB6, PMP22, TAGLN y MMP13.

![Volcano plot representation of differentially expressed genes between MAC-T and MAC-T BLV.\
Mean log2 fold change is plotted against the--log10 FDR for all the expressed genes. Red and blue dots represent genes with a significant increase or decrease expression, respectively.](pone.0234939.g003){#pone.0234939.g003}

DAVID was used to understand the biological functions of the differentially expressed genes ([Fig 4](#pone.0234939.g004){ref-type="fig"}). The Gene Ontology (GO) analysis indicated that the differentially expressed genes were involved in defense response to virus, negative regulation of viral genome replication, organelle fission, response to type I interferon, innate immune response, collagen catabolic process, cellular response to fibroblast growth factor stimulus, induction of positive chemotaxis, skin development and embryo implantation.

![Functional enrichment of differentially expressed genes.\
Most significant GO terms associated with down and upregulated genes. The bar length indicates the significance and equals to the negative logarithm of the p-value. The bar color indicates the number of genes of that pathway that are differentially expressed in MAC-T BLV cells.](pone.0234939.g004){#pone.0234939.g004}

Discussion and conclusion {#sec006}
=========================

Although some studies analyzed the differential gene expression in cell lines transfected with the viral gene *tax* and in BLV infected and uninfected blood cells using microarrays \[[@pone.0234939.ref013],[@pone.0234939.ref014]\], several questions regarding the effect of BLV infection on the cell's transcriptome remain to be addressed. To our knowledge, no prior studies have analyzed the effect of BLV infection on the cell´s transcriptome using RNA seq technology.

Particularly, the bMEC play a crucial role in the onset of the mammary gland immune response. We had previously infected these cells with BLV in order to analyze the effect of the virus on the response against pathogens that could cause mastitis. This is the first report of the transcriptome from bovine mammary epithelial cells (MAC-T) stably infected with BLV. A total of 352 genes were differentially expressed (log2FC ≥ 2, adj p-value ≤ 0.05, and FDR ≤ 0.05). Most of the upregulated genes were related to the host immune response, especially with IFN I signal. Type I IFN plays a crucial role in the antiviral immune response by stimulating the expression of the interferon-stimulated genes (ISG). Many ISG were upregulated in MAC-T BLV cells, including MX2, RSAD2, ISG15, OASL, IFI6, and IFI27. Also some chemokines such as CCL5 and CXCL8 were upregulated. On the other hand, genes related to the collagen catabolic process (SPARC, MMP13, and ADAMTS2) were downregulated.

ISG induce an antiviral response, which aims to block the viral replication in the different stages of the infection. These genes are also upregulated in other viral infections, including West Nile \[[@pone.0234939.ref015]\], Influenza A \[[@pone.0234939.ref016]\], and HIV \[[@pone.0234939.ref017]\]. It has been reported that the upregulation of these genes could cause an immunomodulatory effect that alters the capacity of the neutrophils to recognize and phagocyte pathogenic bacteria \[[@pone.0234939.ref018]\]. Moreover, overexpression of these ISG genes could be detrimental and increase the pathogenicity and susceptibility to bacterial infections \[[@pone.0234939.ref019]--[@pone.0234939.ref021]\]. These results suggest that bovine epithelial mammary cells persistently infected with BLV could have altered their capacity to react to other pathogens.

Epithelial cells are the first barrier in the immune response and express cytokines and chemokines that recruit immune cells to the site of infection. In MAC-T BLV cells, an increase in CCL5 and CXCL8 was observed. Overexpression of these chemokines highlights the important role of the bovine mammary epithelium in the onset of the antiviral immune response and has also been described in other viral infections \[[@pone.0234939.ref022]--[@pone.0234939.ref024]\].

One of the GO terms altered in MAC-T BLV cells is the collagen catabolic process. In this biological pathway, MAC-T BLV cells show a downregulation of genes, including SPARC, MMP19, and ADAMTS2. SPARC plays a role in collagen binding to the basal membrane, and it has been reported that a decrease in this protein is associated with tumor progression and metastasis in bladder cancer and leukemias \[[@pone.0234939.ref025],[@pone.0234939.ref026]\]. MMP13 is a matrix metallopeptidase that cleaves type II collagen and participates in matrix remodeling from physiological and pathological processes \[[@pone.0234939.ref027]\]. ADAMST2 also plays a role in extracellular matrix remodeling. Its main function is to clive collagen precursors, although it also has antitumoral and antiangiogenic properties \[[@pone.0234939.ref028]\]. The downregulation of these genes in MAC-T BLV could be involved in tumor development *in vivo*.

Among the differentially expressed genes in MAC-T BLV, some were related to cancer development, including ADGR1, NmU, PADI2, ID1, DPPA4 y XAF1. Considering that BLV is an oncogenic virus that causes lymphosarcomas, a deeper study of these genes could be useful for a better understanding of the virus pathogenicity and to develop new therapeutic strategies. It is well known that ADGRD1 is a G coupled receptor that plays a role in immune response, angiogenesis, and development \[[@pone.0234939.ref029]\]. Nmu is a neuropeptide that activates an inflammatory state by favoring cytokine expression and eosinophils activation. Overexpression of this protein has been associated with a worst outcome in cancer patients. Nmu overexpression induces cell proliferation, migration, invasion, and apoptosis resistance \[[@pone.0234939.ref030]\]. Moreover, PADI2 is an enzyme whose overexpression was associated with inflammatory process and tumor development \[[@pone.0234939.ref031]\]. ID1 is a DNA binding protein that has an active role in the control of cell proliferation and growth. Its increase has been reported in different types of cancer \[[@pone.0234939.ref032]\]. Many cell lines and cancer tissues present an increased expression of DPPA4, a gene that codifies for a nuclear factor essential during embryogenesis for pluripotential maintenance \[[@pone.0234939.ref033]\].

On the other hand, MAC-T BLV cells show a decreased expression of tumor suppressor genes, including transgrelin (TAGLN) and GJB6. TAGLN is an actin binding protein that is involved in cellular growth, migration, and matrix remodeling. It is believed to inhibit MMP9 activity, an enzyme necessary for tumor migration and invasion. TAGLN downregulation has also been reported in breast cancer \[[@pone.0234939.ref034]\]. Moreover, GJB6 participates in cell cycle regulation and acts as a tumor suppressor gene. Its decreased expression is associated with tumor progression \[[@pone.0234939.ref035]\]. The downregulation of these genes could play a role in tumor development *in vivo* in BLV infected animals. These findings signal the need for additional studies to understand more about the genes implicated in tumor development in BLV infected animals.

Although we found a differential expression of some oncogenes and tumor suppressor genes in this study, there are almost no reports of breast cancer in cattle. BLV infection has been mainly studied in dairy cattle where the animals have high rates of pregnancies that are believed to be protective against breast cancer \[[@pone.0234939.ref036]\]. Notwithstanding, many studies associate BLV with human breast cancer development \[[@pone.0234939.ref036]\]. It would be interesting to analyze if the genes found in this study are also differentially expressed in samples from human breast cancer where BLV fragments were detected. Moreover, it is well known that chronic inflammation is associated with cancer development \[[@pone.0234939.ref037]\]. In that context, the study of the immune-related genes in which altered expression was observed in MAC-T BLV cells would also be interesting.

The PCA analysis showed that 40% of the genetic variation between samples is related to ribosomal complex development and ribosomal RNA metabolism and process, which is active in multiple neoplastic cells with highly increased protein synthesis.\[[@pone.0234939.ref038]\] Ribosomal complex development and ribosomal RNA metabolism and process are component of the ribosome biogenesis, a process needed for cell growth and proliferation. It is well known that people with defects in ribosome biogenesis (called ribosomopathies) are at an increased risk of developing cancer. Moreover, there are some linkages between the neoplastic transformation of chronically inflamed tissues and alterations in ribosome biogenesis \[[@pone.0234939.ref039]\]. Since BLV could be a cause of chronic inflammation, this new information about the alteration in ribosome biogenesis opens a new perspective to analyze the neoplastic effect of BLV infection. Further studies are needed to understand how these factors could contribute to BLV tumor development.

A previous study using microarrays analyzed the differential gene expression in a HeLa cell line transfected with the BLV Tax protein\[[@pone.0234939.ref013]\]. Interestingly and contrary to our findings, they reported that Tax expressing cells decreased the expression of genes involved in the immune response. Particularly, among the downregulated immune genes many were related to the interferon family of anti-viral genes, such as ISG15 and OASL, which we found to be upregulated. The reason for these contradictory results could be the many differences in the studies designs. For instance, in the study performed by Arainga and collaborators they used a human cell line that is not the natural host of the virus; moreover, they only studied the effect of the BLV transactivating protein Tax, while our study analyze the effect of the virus infection in bovine epithelial mammary cells. What is more, in Arainga´s study, differential gene expression was analyzed 24 h after the cells were transfected with Tax, while in our study, RNA extraction was performed on cells at 35 days post-infection with BLV. This is an important difference since we are analyzing the effect of the virus in the long term. BLV is known to cause persistent infections and its main clinical manifestation (that are the lymphosarcomas) appear from 5 to 10 years after the infection. Our intention was to measure the effect of the virus on the cell lines persistently exposed to the virus to see how it could affect the immune function of those cells and to evaluate if there were differentially expressed genes that could play a role in the neoplastic process that leads to the lymphosarcomas.

A microarrays study performed in 2017 by Brym and Kamiński on whole blood from BLV infected and uninfected cattle shows that the virus induced differential expression of genes related to the innate immune response and the neoplastic transformation \[[@pone.0234939.ref014]\]. Although we found some similar enriched pathways in our study, most of our differentially expressed genes were upregulated, in contrast with Brym´s results, where a greater number of downregulated genes were found. In line with that disparity, the only two differentially expressed genes present in both studies had different expressions: CXCL8 and CTSL were downregulated in Brym\`s study and upregulated in ours. It is believed that BLV remains silent in PBMCs *in vivo*, and *ex vivo* incubation of those cells immediately activates the virus expression. In Brym\`s study, samples were inactivated right after bleeding, which means that the results they found probably reflect what is happening *in vivo* in BLV silently infected cells. On the other hand, our study was performed in persistently infected BLV cell lines that actively release the virus. The amount of viral sequences identified in each MAC-T BLV sample is available in [S2 Table](#pone.0234939.s003){ref-type="supplementary-material"}. Our study probably reflects the stage of the disease where there is an increased viral expression. Although many neoplastic related genes were found, none of them were shared between both studies.

In summary, this *in vitro* transcriptome analysis gives further insight into the BLV infection effect on a bovine mammary epithelial cell line, highlighting important genes in the viral immune response and the tumorigenic process. The genes identified in this study could be potential targets of intervention for vaccine development or therapeutic strategies. Moreover, a further study of those genes could help to elucidate if BLV is related to human breast cancer. On the other hand, our findings demonstrate an upregulation of many interferon-induced genes that could be affecting the mammary epithelial immune response. Previously, the increase of IFN I pathway was associated with greater susceptibility to bacterial infection. Taking that into account, future research should investigate how the increase of IFN I pathway on bMEC could affect the local immune response against pathogens causative of mastitis.

Supporting information {#sec007}
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Line 123-126 and Figure 5 - Is not the aim of the study but if BLV sequence obtained from MAC-T BLV has been already phylogenetically characterised, it would be interesting to classify it in terms of genotypes. Moreover, the tree could also contain sequences from the United States. On a tree there is a mistake - the sequence LC164083 is not a Sheep but come from FLK-BLV cells.

Discussion and conclussion

Line 145 West Nile

It is surprising that Authors do not discuss their results with thealready mentioned papers Arainga et al and Brym, Kaminski; for example the CXCL8 proteins was also mentioned as DEG at Brym paper. The authors themselves have already done some expressive RTqPCR tests on this line - whether there was any reflection of the results in RNAseq? - for example TLR9.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Chengming Wang

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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7 May 2020

Reviewer \#1:

This group published two BLV-related manuscript in 2018 (Stable infection of a bovine mammary epithelial cell line (MAC-T) with bovine leukemia virus (BLV).), and in 2019 (Effect of bovine leukemia virus on bovine mammary epithelial cells.). This work is a continuation of the previous studies while RNAseq was performed to observe the impact of BLV infection on the transcriptome of bovine mammary epithelial cells.

The authors are encouraged to revise this manuscript so that the readers can understand and follow your manuscript well. Each figure should have its own detailed figure legend. You do not have to leave the Figures in the end of this manuscript while put the title of figure inside of the main text. Large table such as Table-2 can be moved to the supplementary Tables.

Following your suggestion Table 2 was moved to supplementary information. All figures are now submitted in an individual file as requested by the journal and the captions in the manuscript have a detailed legend.

This manuscript has two parts: the part-1 is about the RNAseq, and the part-2 is related to the BLV sequencing. It is my opinion that the authors may consider to remove the part-2 totally from this manuscript. You obtained a viral sequence of 8419 pb that represents 96.6% of the complete genome, and this is not enough for BLV as a retrovirus. Then, you use the sequence with 96.8% of coverage to perform phylogenetic comparison, and it is not valid to have the statement (showed a 99% homology with reported Japanese viral genomes).

Following your suggestion the BLV sequencing was removed from the manuscript.

Please focus on the part-1 of your research, and come up with more specific take-home messages from the analysis of the RNAseq (more information that what you have now: BLV infected MAC-T cells have an altered expression of INF I signal pathway and genes involved in defense response to virus, as well as a collagen catabolic process and some protooncogenes and tumor suppressor genes).

Thank you for this suggestion. We enriched the discussion section and specially the last summarizing paragraph in order to give a better take home message.

Reviewer \#2:

Title- just suggestion - to add that the transcriptomic analysis was done with the RNAseq method would be more informative

Taking your suggestion, the title was changed to "Effect of bovine leukemia virus (BLV) infection on bovine mammary epithelial cells RNA-seq transcriptome profile."

Abstract - line 21 - should be: the RNA seq data.

Thanks for the correction. All the information regarding the genome sequence obtained by RNA seq was deleted following reviewer 1 suggestion.

Materials and methods

\- Preparation of experimental material should be more precisely written- how the biological replicate of the experiment were prepared? Were the cultures of MAC-T and MAC-T BLV conducted and harvested in parallel? Was total RNA isolated from each repetition at the same time? These questions will be reflected in the comments on the results.

This are very good observations. We increased the details on the sample preparation answering your specific questions. how the biological replicate of the experiment were prepared? Each biological replicate consisted of MAC-T cells infected with the same batch of PBMCs obtained from a cow infected with BLV. Were the cultures of MAC-T and MAC-T BLV conducted and harvested in parallel? Cultures were passaged upon approaching confluence using standard techniques and MAC-T cells were always passed in first place. MAC-T BLV cells were subcultured after MAC-T to avoid cross-contamination. Was total RNA isolated from each repetition at the same time? No. All the cell lines were harvested for RNA extraction when they reached confluency.

\- The RNA seq data were prepared by the sequencing platform - where? any company name? If whole bioinformatic analysis were done by Authors or any Center for Informatics?

Thank you for highlighting this, we recognize it was not clear in the original manuscript. I copy the new statement: "Samples were sequenced by Novogene Corporation (<https://en.novogene.com>), who constructed the cDNA library by using RNA - NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA, USA). The sequencing performed in the NovaSeq 6000 (Illumina, San Diego, CA, USA) resulted in 150 pb paired-end sequences. The analysis of the sequencing images and the Fasta file creation was done with the software Casava v1.8.2 (Illumina, San Diego, CA, USA). The data sent by Novogene Corporation were analyzed by our laboratory."

As far as I know for PLOS ONE Authors contributions is required.

A file with each author\`s contribution is attached with the manuscript.

Results

Fig.1 and line 87-89 - will be more informative which program was used for compute the heat map ans some datails for scale bar is missing.

The program used for the analysis is now indicated clearly in the following sentence: "The hierarchical clustering analysis done by the platform IDEP revealed that MAC-T samples segregate differently than MAC-T BLV, suggesting that BLV infection affects the bovine mammary epithelial cell´s transcriptome (Fig 1)." And a new picture was obtained where the scale bar is more readable.

It is true that hierarchical analysis revealed that MAC-T samples segregate differently than MAC-T BLV but also showes that intra-group variability is high, only mactblv1 and mactblv2 are similar. In the results section RIN data are missing. Here the way of preparation of experimental material could be significant. The number of 352 genes differentially expressed might be real but there is some kind of doubt that intra-group variability can affect this. Please comment and explain\...

The RIN data is now added as supplementary material. The RIN is not significantly different among samples from MAC-T or MAC-T BLV groups. The difference could be due to biological variations. Particularly, in MAC-T group the difference observed could be a cause of the different passages used for the analysis.

Fig.2 and line 92-95

Will be more informative when samples on the PCA plot have the same, corresponding name as in the heat map as mactblv1\....It seems that the top one red point probably showed differential RNA-seq quality? Please comment\...

The figure is modified and now shows the names of the samples. We added a comment in the manuscript that states: " As observed in the heat map, mact 1 sample is quite different from mact2 and mact 3; however, there is no difference in RNA quality between the samples (available in S1 Text)."

There is an information that the genetic variation between samples is related to ribosomal complex development

and ribosomal RNA metabolism and process- commentary on these results is not visible in the discussion. Why?

We are sorry we did not include a comment on that finding. We now added a paragraph in the discussion section about that: "The PCA analysis showed that 40% of the genetic variation between samples is related to ribosomal complex development and ribosomal RNA metabolism and process, which is active in multiple neoplastic cells with highly increased protein synthesis.(37) Ribosomal complex development and ribosomal RNA metabolism and process are component of the ribosome biogenesis, a process needed for cell growth and proliferation. It is well known that people with defects in ribosome biogenesis (called ribosomopathies) are at an increased risk of developing cancer. Moreover, there are some linkages between neoplastic transformation of chronically inflammated tissues and alterations in ribosome biogenesis (38). Since BLV could be a cause of chronic inflammation, this new information about the alteration in ribosome biogenesis opens a new perspective to analyze the neoplastic effect of BLV infection. Further studies are needed to understand how these factors could contribute to BLV tumor development."

Line 97-98, tab.2 and 138 -the data should be compatible fold change or log2FC?

It is log2FC in all cases. We corrected that in materials and methods.

Line 123-126 and Figure 5 - Is not the aim of the study but if BLV sequence obtained from MAC-T BLV has been already phylogenetically characterised, it would be interesting to classify it in terms of genotypes. Moreover, the tree could also contain sequences from the United States. On a tree there is a mistake - the sequence LC164083 is not a Sheep but come from FLK-BLV cells.

The phylogenetic analysis was removed from the manuscript following Reviewer 1 suggestion.

Discussion and conclussion

Line 145 West Nile. Modified

It is surprising that Authors do not discuss their results with thealready mentioned papers Arainga et al and Brym, Kaminski; for example the CXCL8 proteins was also mentioned as DEG at Brym paper. The authors themselves have already done some expressive RTqPCR tests on this line - whether there was any reflection of the results in RNAseq? - for example TLR9.

Thank you for this suggestion. We specifically added two paragraphs to discuss the results by Arainga and Brym. However, we excluded a discussion about our previous results because those were done in a different infectious stage.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234939.r003

Decision Letter 1

Ortega-Villaizan

Maria del Mar

Academic Editor

© 2020 Maria del Mar Ortega-Villaizan

2020

Maria del Mar Ortega-Villaizan

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 Jun 2020

"Effect of bovine leukemia virus (BLV) infection on bovine mammary epithelial cells RNA-seq transcriptome profile."

PONE-D-20-07350R1

Dear Dr. Ceriani,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Maria del Mar Ortega-Villaizan

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The reviewers comments have been adressed. Just check one more correction by Reviewer 2. The manuscript is ready for publication.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Appreciate the efforts from the authors to revise this manuscript. A great job by the authors to address this reviewer\'s comments.

Reviewer \#2: Please check - line 59 - passage 35 and line 214 - 35 days after infection - whether this is compatible with each other?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Chengming Wang

Reviewer \#2: No
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Dear Dr. Ceriani:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maria del Mar Ortega-Villaizan

Academic Editor
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